Comparing two drug combinations for newly diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different combinations of chemotherapy drugs for adults newly diagnosed with acute myeloid leukemia (AML). One combination uses newer targeted drugs, while the other is a standard treatment. The goal is to see which approach works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been newly diagnosed with AML (not acute promyelocytic leukemia or AML that started from a previous blood disorder or cancer treatment).
- You are healthy enough to receive intensive chemotherapy.
- Your liver and kidney function are within acceptable limits.
- You have not had prior treatment for AML (except for managing high white blood cell counts) and have not taken drugs like azacitidine or venetoclax before.
- You do not have significant heart problems, uncontrolled infections, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This trial compares two different strengths of a chemotherapy regimen that includes venetoclax (a targeted pill) for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find which dose works as well or better with fewer side effects, and it may offer a more personalized treatment option for those who can tolerate intensive therapy.
This trial tests a combination of three drugs for treating newly diagnosed AML in older or frailer patients. The goal is to see if this combination is safe and effective, providing a gentler option for those who cannot handle standard intensive chemotherapy.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
This study compares two chemotherapy combinations for older adults newly diagnosed with acute myeloid leukemia (AML) that has certain gene changes (NPM1 or IDH1/IDH2). The goal is to see if the new combination works better and has fewer side effects than the standard one.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.